Drugs / GSK239512
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00675090 | Feb 2008 → Jun 2009 | Alzheimer disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00474513 | Mar 2007 → Mar 2008 | cognitive impairment with or without cerebellar ataxia, dementia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT01772199 | Feb 2013 → Sep 2014 | relapsing-remitting multiple sclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01009060 | Dec 2009 → Aug 2011 | schizophrenia | GlaxoSmithKline | Completed | Missed primary |
| Phase 2 | NCT01009255 | Nov 2009 → Nov 2010 | Alzheimer disease | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01802931 Comparator | Jan → Apr 2013 | multiple sclerosis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK239512 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00474513 ↗ |
| Known as | GSK-239512A | ChEMBL registry synonym — accepted as the source's own label CHEMBL3092650 ↗ |
| Action | Inhibit | “GSK239512, a Histamine H3 Antagonist” NCT00474513 ↗1“Histamine H3 receptor antagonist” CHEMBL3092650 ↗ |
| Modality | Small molecule | — CHEMBL3092650 ↗ |
| Route | Oral | “after receiving an oral dose of the drug” NCT00474513 ↗ |
| Target | HRH3 | “Histamine H3 receptor antagonist” CHEMBL3092650 ↗ |